Larimar Therapeutics, Inc. (LRMR)
- Previous Close
2.3500 - Open
2.3200 - Bid 2.3600 x 200
- Ask 2.4300 x 200
- Day's Range
2.2750 - 2.4600 - 52 Week Range
1.6100 - 11.2000 - Volume
784,287 - Avg. Volume
815,813 - Market Cap (intraday)
153.027M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3200 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.96
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
larimartx.comRecent News: LRMR
View More
Performance Overview: LRMR
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LRMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LRMR
View MoreValuation Measures
Market Cap
153.03M
Enterprise Value
-25.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.36%
Return on Equity (ttm)
-63.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-80.6M
Diluted EPS (ttm)
-1.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
183.45M
Total Debt/Equity (mrq)
2.98%
Levered Free Cash Flow (ttm)
-42.05M